Duality Biologics (Suzhou) Co. Ltd., a clinical-stage biotech company focused on next generation antibody-drug conjugate therapeutics to treat cancer and autoimmune diseases, has expanded  its collaboration with BioNTech SE to develop, manufacture and commercialize a third ADC candidate DB-1305 globally, excluding Mainland China, Hong Kong and Macau Special Administrative Regions. DB-1305 is currently in a Phase 1/2 clinical trial (NCT05438329) for solid tumors. 
 
Under the agreements, DualityBio will receive upfront payments, additional development, regulatory and commercial milestones, and royalties on sales of DB-1305. BioNTech will hold commercial rights globally (excluding Mainland China, Hong Kong and Macau Special Administrative Regions), where DualityBio will retain commercial rights.
 
DB-1305, a third generation Trop2 ADC molecule built from DualityBio’s Duality Immune Toxin Antibody Conjugates (DITAC) platform, exhibited potent antitumor activity in preclinical tumor models and robust clinical efficacy in NSCLC and other solid tumors.